683 related articles for article (PubMed ID: 33031623)
1. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O; Lai WF
Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
Shahrbaf MA; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
Kundu S; Sarkar D
Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
[TBL] [Abstract][Full Text] [Related]
6. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatment strategies for COVID-19 infection.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Korompoki E; Fotiou D; Migkou M; Tzanninis IG; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
Clin Exp Med; 2021 May; 21(2):167-179. PubMed ID: 33128197
[TBL] [Abstract][Full Text] [Related]
8. An effective drug against COVID-19: reality or dream?
Yaghoubi A; Amel Jamehdar S; Movaqar A; Milani N; Soleimanpour S
Expert Rev Respir Med; 2021 Apr; 15(4):505-518. PubMed ID: 33215942
[No Abstract] [Full Text] [Related]
9. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
Maciorowski D; Ogaugwu C; Durvasula SR; Durvasula R; Kunamneni A
SLAS Discov; 2021 Mar; 26(3):311-329. PubMed ID: 33319627
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Mehta N; Mazer-Amirshahi M; Alkindi N; Pourmand A
Am J Emerg Med; 2020 Jul; 38(7):1488-1493. PubMed ID: 32336586
[TBL] [Abstract][Full Text] [Related]
11. Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.
Ueda M; Tanimoto T; Murayama A; Ozaki A; Kami M
Clin Pharmacol Ther; 2022 Mar; 111(3):545-547. PubMed ID: 33882157
[No Abstract] [Full Text] [Related]
12. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM
Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Lai CC; Chao CM; Hsueh PR
J Microbiol Immunol Infect; 2021 Oct; 54(5):767-775. PubMed ID: 34253490
[TBL] [Abstract][Full Text] [Related]
14. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir: a pendulum in a pandemic.
Schwartz IS; Heil EL; McCreary EK
BMJ; 2020 Nov; 371():m4560. PubMed ID: 33234523
[No Abstract] [Full Text] [Related]
16. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
[TBL] [Abstract][Full Text] [Related]
17. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
[TBL] [Abstract][Full Text] [Related]
18. COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Raj CTD; Kandaswamy DK; Danduga RCSR; Rajasabapathy R; James RA
Arch Microbiol; 2021 Jul; 203(5):2043-2057. PubMed ID: 33555378
[TBL] [Abstract][Full Text] [Related]
19. Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients.
Demir Önder K; Seremet Keskin A; Berk H; Seyman D; Öztoprak N
Turk J Med Sci; 2021 Dec; 51(6):2835-2849. PubMed ID: 34418000
[TBL] [Abstract][Full Text] [Related]
20. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma.
Ramzy S; Abdelazim AH; Osman AO; Hasan MA
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Nov; 281():121625. PubMed ID: 35863184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
